Insider · CIK 0002027010
Andrea S. James
cfoofficer
Files at IMDX (Oncocyte Corp). First filing Dec 9, 2024, latest Feb 11, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
2 / 0
$246k bought, $0 sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
IMDX: Oncocyte Corp
IMDXOct 9, 2026 · close 3.37
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 57Moderate | Oncocyte Corp | $200k 97,561 shares | +182% | - | |
| 38Weak | IMDXbuy Oncocyte Corp | $46k 20,000 shares | +59% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 26, 2025 | IMDX Oncocyte Corp | AGrant or award Restricted Stock Unitsderivative | +113,207 | $0.00 | $0 | 113,207 | Mar 28, 2025 |
| Feb 7, 2025 | IMDX Oncocyte Corp | POpen-market purchase Common Stock, no par value | +97,561 | $2.05 | $200k | 151,231 | Feb 11, 2025 |
| Dec 5, 2024 | IMDX Oncocyte Corp | POpen-market purchase Common Stock, no par value | +20,000 | $2.29 | $46k | 53,670 | Dec 9, 2024 |
| Oct 11, 2024 | IMDX Oncocyte Corp | AGrant or award Options to Purchase Common Stockderivative | +200,000 | $0.00 | $0 | 200,000 | Oct 15, 2024 |
| Oct 11, 2024 | IMDX Oncocyte Corp | AGrant or award Restricted Stock Unitsderivative | +100,000 | $0.00 | $0 | 100,000 | Oct 15, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.